Updated June 27 at 10:27am
Biotechnology
60 results total, viewing 41 - 50
Biotechnology giant Amgen Inc. posted third- quarter earnings that topped analysts’ estimates, driven by higher drug sales, and raised its forecast for the year. more
I’m seeing lots of news reports about the end of the new Silicon Valley tech “bubble.” I put that word in quotes because the current situation doesn’t look much like the bubble of the late 1990s. But there still might soon be a broad drop in funding for startups, and a fall in the valuations of these companies. more
Brown University leaders will break ground Thursday evening on an $88 million School of Engineering building that will focus on nanoscience and bioengineering research. more
CVS Health Corp. pays among the highest taxes in the nation, according to WalletHub, which released its S&P 100 tax rates report on Wednesday. more
Rhode Island Medical Imaging has acquired Radiology Associates, a radiology practice. more
(Updated, 9:20 p.m.) IlluminOss Medical has appointed Manny Avila as its new president and CEO. The developer of a minimally invasive system to repair bone fractures has been looking for a chief executive since former president and CEO Dirk Kuyper left in September 2014. more
Diane Hoffman-Kim is associate professor of medical science and engineering in the Department of Molecular Pharmacology, Physiology, and Biotechnology, and the Center for Biomedical Engineering at Brown University. She was lead author on a recent study showing how miniature brains can be developed in the laboratory for research purposes at surprisingly low cost. more
Mnemosyne Pharmaceuticals has changed its name to Luc Therapeutics and moved its headquarters from Providence to Cambridge. more
Beltone New England, a national leader in hearing care, is hosting a “Hear for Children” campaign throughout the rest of September to raise funds for pediatric audiology at Hasbro Children’s Hospital. more
Last week Nabsys Inc. shut its doors, costing approximately 40 people their jobs and investors about $50 million. That's the nature of the beast in the high-risk biotech field. But by some of the reaction to the company's failure, it is … more
« Prev | 1 | 2 | 3 | 4 | 5 | 6 Next »